- Home
- CSCI vs NLSP Comparison
CSCI vs NLSP Comparison
Compare CSCI & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSCI
- NLSP
- Stock Information
- Founded
- CSCI 1990
- NLSP 2015
- Country
- CSCI Canada
- NLSP Switzerland
- Employees
- CSCI N/A
- NLSP N/A
- Industry
- CSCI
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- CSCI
- NLSP Health Care
- Exchange
- CSCI NYSE
- NLSP Nasdaq
- Market Cap
- CSCI 10.6M
- NLSP 12.4M
- IPO Year
- CSCI 1996
- NLSP 2021
- Fundamental
- Price
- CSCI $3.41
- NLSP $2.86
- Analyst Decision
- CSCI
- NLSP
- Analyst Count
- CSCI 0
- NLSP 0
- Target Price
- CSCI N/A
- NLSP N/A
- AVG Volume (30 Days)
- CSCI 2.3K
- NLSP 385.9K
- Earning Date
- CSCI 08-12-2025
- NLSP 07-07-2025
- Dividend Yield
- CSCI N/A
- NLSP N/A
- EPS Growth
- CSCI N/A
- NLSP N/A
- EPS
- CSCI N/A
- NLSP N/A
- Revenue
- CSCI $9,030,000.00
- NLSP N/A
- Revenue This Year
- CSCI N/A
- NLSP N/A
- Revenue Next Year
- CSCI N/A
- NLSP N/A
- P/E Ratio
- CSCI N/A
- NLSP N/A
- Revenue Growth
- CSCI 36.51
- NLSP N/A
- 52 Week Low
- CSCI $1.96
- NLSP $1.30
- 52 Week High
- CSCI $7.54
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- CSCI N/A
- NLSP 68.80
- Support Level
- CSCI N/A
- NLSP $2.51
- Resistance Level
- CSCI N/A
- NLSP $3.08
- Average True Range (ATR)
- CSCI 0.00
- NLSP 0.21
- MACD
- CSCI 0.00
- NLSP 0.04
- Stochastic Oscillator
- CSCI 0.00
- NLSP 75.17
About CSCI COSCIENS BIOPHARMA INC
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.